Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes
MetadataShow full item record
Pancreatic cancer is a highly lethal malignancy with few effective therapies. We performed exome sequencing and copy number analysis to define genomic aberrations in a prospectively accrued clinical cohort (n = 142) of early (stage I and II) sporadic pancreatic ductal adenocarcinoma. Detailed analysis of 99 informative tumours identified substantial heterogeneity with 2,016 non-silent mutations and 1,628 copy-number variations. We define 16 significantly mutated genes, reaffirming known mutations (KRAS, TP53, CDKN2A, SMAD4, MLL3, TGFBR2, ARID1A and SF3B1), and uncover novel mutated genes including additional genes involved in chromatin modification (EPC1 and ARID2), DNA damage repair (ATM) and other mechanisms (ZIM2, MAP2K4, NALCN, SLC16A4 and MAGEA6). Integrative analysis with in vitro functional data and animal models provided supportive evidence for potential roles for these genetic aberrations in carcinogenesis. Pathway-based analysis of recurrently mutated genes recapitulated clustering in core signalling pathways in pancreatic ductal adenocarcinoma, and identified new mutated genes in each pathway. We also identified frequent and diverse somatic aberrations in genes described traditionally as embryonic regulators of axon guidance, particularly SLIT/ROBO signalling, which was also evident in murine Sleeping Beauty transposon-mediated somatic mutagenesis models of pancreatic cancer, providing further supportive evidence for the potential involvement of axon guidance genes in pancreatic carcinogenesis.
Showing items related by title, author, creator and subject.
Molecular mechanism underlying aberrant expression of the connective tissue growth factor in paediatric pre-B cell acute lymphoblastic leukemiaWelch, Mathew D. (2011)Acute lymphoblastic leukaemia (ALL) is the most common cancer diagnosed in children aged 1-14 years. There have been vast improvements in clinical outcomes for children diagnosed with ALL with cure rates of up to 90% ...
In vitro characterization of the a-thalassemia point mutation HBA2:c.95+1G>A [IVS-I-1(G>A) (a2)]Qadah, T.; Finlayson, J.; Ghassemifar, Reza (2012)The a-thalassemias are a group of disorders occurring as a result of decreased synthesis of a-globin chains, most commonly due to deletions of a-globin genes. Detection of a-thalassemia (a-thal) caused by point mutations ...
Collisson, E.; Campbell, J.; Brooks, A.; Berger, A.; Lee, W.; Chmielecki, J.; Beer, D.; Cope, L.; Creighton, C.; Danilova, L.; Ding, L.; Getz, G.; Hammerman, P.; Hayes, D.; Hernandez, B.; Herman, J.; Heymach, J.; Jurisica, I.; Kucherlapati, R.; Kwiatkowski, D.; Ladanyi, M.; Robertson, G.; Schultz, N.; Shen, R.; Sinha, R.; Sougnez, C.; Tsao, M.; Travis, W.; Weinstein, J.; Wigle, D.; Wilkerson, M.; Chu, A.; Cherniack, A.; Hadjipanayis, A.; Rosenberg, M.; Weisenberger, D.; Laird, P.; Radenbaugh, A.; Ma, S.; Stuart, J.; Byers, L.; Baylin, S.; Govindan, R.; Meyerson, M.; Gabriel, S.; Cibulskis, K.; Kim, J.; Stewart, C.; Lichtenstein, L.; Lander, E.; Lawrence, M.; Getz, E.; Fulton, R.; Fulton, L.; McLellan, M.; Wilson, R.; Ye, K.; Fronick, C.; Maher, C.; Miller, C.; Wendl, M.; Cabanski, C.; Mardis, E.; Wheeler, D.; Balasundaram, M.; Butterfield, Y.; Carlsen, R.; Chuah, E.; Dhalla, N.; Guin, R.; Hirst, C.; Lee, D.; Li, H.; Mayo, M.; Moore, R.; Mungall, A.; Schein, J.; Sipahimalani, P.; Tam, A.; Varhol, Richard; Robertson, A.; Wye, N.; Thiessen, N.; Holt, R.; Jones, S.; Marra, M.; Imielinski, M.; Onofrio, R.; Hodis, E.; Zack, T.; Helman, E. (2014)Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy ...